Among the 72 patients (18%) who did not complete the study, the most common reasons for discontinuation
were AEs (4% in placebo, 4% in ESL 400-mg, 8% in ESL 800-mg, and 20% in ESL 1,200-mg groups Fig. 2) and
withdrawal of consent (8% of patients in placebo group, 4% in ESL 400- and 1,200-mg groups, and 2% in ESL 800-mg group).